natgillin/translations-raw huggingface dataset:
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis. 
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Memantine Mylan ponovno ocenjevati v rednih intervalih.
This means that Memantine Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Ebixa. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Ebixa.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Mylan by the patient. 
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Memantine Mylan.
The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Mylan on 22 April 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Memantine Mylan, veljavno po vsej Evropski uniji, odobrila dne 22. aprila 2013.
Memantine Mylan is available as 10 mg and 20 mg tablets and can only be obtained with a prescription. 
Zdravilo Memantine Mylan je na voljo v obliki 10- in 20-miligramskih tablet in se izdaja le na recept.
Because Memantine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Memantine Mylan generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What are the benefits and risks of Memantine Mylan? 
Kakšne so koristi in tveganja, povezani z zdravilom Memantine Mylan?
The full EPAR for Memantine Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Memantine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Memantine Mylan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease. 
kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršno je opaziti pri Alzheimerjevi bolezni.
In addition, overstimulation of the NMDA receptors may result in cell damage or death. 
Poleg tega lahko prekomerna stimulacija receptorjev NMDA
Safety information has been included in the summary of product characteristics and the package leaflet for Memantine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients. 
V povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Memantine Mylan so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Because Memantine Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa. 
Ker je zdravilo Memantine Mylan generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Ebixa.
What is Memantine Mylan and what is it used for? 
Kaj je zdravilo Memantine Mylan in za kaj se uporablja?
For practical information about using Memantine Mylan, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Memantine Mylan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Other information about Memantine Mylan 
Druge informacije o zdravilu Memantine Mylan
Memantine Mylan is a ‘generic medicine'. 
Zdravilo Memantine Mylan je „generično“ zdravilo.
The active substance in Memantine Mylan, memantine, is an antidementia medicine. 
Zdravilna učinkovina zdravila Memantine Mylan, memantin, je zdravilo za zdravljenje demence.
Why is Memantine Mylan approved? 
Zakaj je bilo zdravilo Memantine Mylan odobreno?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Mylan has been shown to have comparable quality and to be bioequivalent to Ebixa. 
da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Memantine Mylan primerljivo raven kakovosti kot zdravilo Ebixa ter da mu je biološko enakovredno.
It is not intended to provide practical advice on how to use Memantine Mylan. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How has Memantine Mylan been studied? 
Kako je bilo zdravilo Memantine Mylan raziskano?
How is Memantine Mylan used? 
Kako se zdravilo Memantine Mylan uporablja?
How does Memantine Mylan work? 
Kako zdravilo Memantine Mylan deluje?
These measures help protect the environment. 
Takšni ukrepi pomagajo varovati okolje.
It is very important that you read and understand the information about this serious reaction. 
Zelo pomembno je, da preberete in razumete informacije o tej resni reakciji.
So it is very important to talk to your doctor about any changes in your health. 
Zato je zelo pomembno, da se s svojim zdravnikom pogovorite o kakršnikoli spremembi vašega zdravstvenega stanja.
Date of latest renewal: 2 January 2011 
Datum zadnjega podaljšanja: 2. januar 2011
You need to be aware of the extra risks: 
Zavedati se morate dodatnih tveganj:
“Pull here” (with Alert card attached) 
“Povlecite tukaj” (s pritrjeno opozorilno kartico)
ATC Code: J05AR04. 
Oznaka ATC: J05AR04.
Your doctor will monitor the effectiveness of your treatment. 
Zdravnik bo nadzoroval učinkovitost vašega zdravljenja.
Don't drive or operate machines unless you're feeling well. 
Ne upravljajte vozil ali strojev, če se ne počutite dobro.
These adverse reactions have often been transitory. 
Ti učinki so bili pogosto prehodni.
Risk Management Plan (RMP) 
• Načrt za obvladanje tveganja (RMP)
32 weeks 26 % 144 weeks 
32 tednov 144 tednov
See sections 4.4 and 4.8 
Glejte poglavji 4.4 in 4.8.
( see reverse of card) 
(glej hrbtno stran kartice)
• deep, rapid, difficult breathing 
• globoko, hitro, težko dihanje,
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 2 January 2001 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 2. januar 2001
This helps your body to increase the CD4 cell count in your blood. 
To pomaga vašemu telesu, da poveča število celic CD4 v krvi.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines webportal 
Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
If you have any of the symptoms listed above or any other symptoms that worry you: 
Če imate katerega od zgoraj naštetih simptomov ali kakršnekoli druge simptome, ki vas skrbijo:
Write your doctor's details below: 
Spodaj si zapišite podatke o svojem zdravniku:
If you are breast-feeding, or thinking about breast-feeding: 
Če dojite ali razmišljate o dojenju:
However, it is not clear whether these cases were due to treatment with these medicinal products or to the underlying HIV disease. 
Vendar ni pojasnjeno, če so bili ti primeri posledica zdravljenja s temi zdravili ali posledica osnovne HIV bolezni.
The anaemia may necessitate transfusions. 
Zaradi anemije utegnejo biti potrebne transfuzije.
Median Change vRNA (log10 c/mL) 
Mediana sprememba vRNA (log10 c/ml)
2) you get one or more symptoms from at least TWO of the following groups 
2) opazite enega ali več simptomov iz vsaj DVEH naslednjih skupin:
• difficulty in sleeping (insomnia) 
• težave s spanjem (nespečnost),
In this patient population, hypersensitivity reactions are particularly difficult to identify. 
tej populaciji bolnikov je preobčutljivostne reakcije še posebej težko prepoznati.
These symptoms are probably caused by the body's immune system becoming stronger, so that the body starts to fight these infections. 
Ti simptomi so verjetno posledica okrepitve imunskega sistema, zaradi česar se organizem začne boriti proti tem okužbam.
What Trizivir is and what it is used for 
Kaj je zdravilo Trizivir in za kaj ga uporabljamo
If you have taken Trizivir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. 
Če ste zdravilo Trizivir jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo spremljal razvoj vašega otroka.
Following discontinuation of abacavir, the symptoms of the reaction should be treated according to local standard of care. 
Po prekinitvi zdravljenja z abakavirjem, je treba simptome reakcije obravnavati v skladu z lokalnimi standardi oskrbe.
Take the tablets at regular times, leaving approximately 12 hours between each tablet. 
Tablete jemljite v rednih presledkih; med eno in drugo tableto naj mine približno 12 ur.
Due to the high proportion of premature discontinuation (42 % of patients discontinued randomised treatment by week 48), no definitive conclusion can be drawn regarding the equivalence between the treatment regimens at week 48. 
Zaradi visokega odstotka prezgodnjih prekinitev zdravljenja (pri 42 % bolnikov je bilo randomizirano zdravljenje prekinjeno v 48. tednu) v 48. tednu ni bilo mogoče sprejeti dokončnih zaključkov o ekvivalentnosti obeh zdravljenj.
A small amount of the ingredients in Trizivir can also pass into your breast milk. 
Majhna količina sestavin zdravila Trizivir lahko prehaja v materino mleko.
No unexpected adverse reactions were reported. 
pri čemer niso poročali o nobenih nepričakovanih neželenih učinkih.
CD4 cells are a type of white blood cell that are important in helping your body to fight infection. 
Celice CD4 so vrsta belih krvnih celic, pomembnih za premagovanje okužb.
• probenecid, to treat gout and similar conditions, and given with some antibiotics to make them more effective 
• probenecid za zdravljenje protina in podobnih stanj ali v kombinaciji z nekaterimi antibiotiki za povečanje njihove učinkovitosti,
They are listed by body system, organ class and absolute frequency. 
Navedene so glede na organski sistem in absolutno pogostnost.
• if they are also taking anti-inflammatory medicines called corticosteroids 
• ki jemljejo tudi protivnetna zdravila, imenovana kortikosteroidi,
It can be life-threatening, causing failure of internal organs. 
Lahko je smrtno nevarna in povzroči lahko odpoved notranjih organov.
It cannot be excluded that abacavir may increase the risk of having a heart attack. 
Ne moremo izključiti, da bi bil abakavir povezan s povečanim tveganjem za srčni infarkt.
If you have stopped taking Trizivir for any reason - especially because you think you are having side effects, or because you have other illness: 
Če ste zdravilo Trizivir nehali jemati zaradi kakršnegakoli razloga - še zlasti če menite, da imate neželene učinke, ali ker imate druge bolezni:
If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time 
Če predložitev PSUR in posodobitev RMP sovpadata, se ju lahko predloži istočasno.
Trizivir helps to control your condition. 
Zdravilo Trizivir pomaga, da je vaše stanje pod nadzorom.
It is rare; if it happens, it usually develops after a few months of treatment. 
Če se pojavi, se po navadi razvije po nekaj mesecih zdravljenja.
These haematological effects are not usually observed before four to six week's therapy. 
Ti hematološki učinki se navadno ne pojavijo prej kot po štirih do šestih tednih zdravljenja.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you 
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
SIDE 1 
STRAN 1
There was no significant difference in the time to first virologic failure (p=0.73, log-rank test) between the 2 arms. 
Čas do prvega pojava virološkega neuspeha se med obema skupinama ni pomembneje razlikoval (p = 0,73, log-rank test).
Hypersensitivity Reactions (see also section 4.8 ): 
Preobčutljivostne reakcije (glejte tudi poglavje 4.8):
Not everyone responds to treatment with Trizivir in the same way. 
Na zdravilo Trizivir se ne odzovejo vsi ljudje enako.
The effects of higher doses are not known. 
Učinki večjih odmerkov niso znani.
For patients with advanced symptomatic HIV disease, it is generally recommended that blood tests are performed at least every two weeks for the first three months of therapy and at least monthly thereafter. 
Pri bolnikih z napredovalo simptomatsko HIV boleznijo je priporočljivo, da se krvne preiskave v prvih treh mesecih zdravljenja opravljajo vsaj vsaka dva tedna, pozneje pa najmanj enkrat na mesec.
Based on the above patients are advised to contact their physician immediately to determine whether they should stop taking abacavir if: 
Na podlagi omenjenega je treba bolnikom naročiti, naj se takoj posvetujejo s svojim zdravnikom, da bodo ugotovili, ali morajo prenehati jemati abakavir, če:
Trizivir should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine. 
Zdravila Trizivir se ne sme jemati skupaj s katerimkoli zdravilom, ki vsebuje lamivudin ali z zdravilom, ki vsebuje emtricitabin.
Studies with abacavir demonstrate a CSF to plasma AUC ratio of between 30 to 44 %. 
Študije z abakavirjem so pokazale razmerje AUC med CST in plazmo med 30 do 44 %.
Trizivir can be taken with or without food. 
Zdravilo Trizivir se lahko jemlje s hrano ali brez nje.
Hertfordshire, SG 12 0DJ, UK 
Hertfordshire, SG 12 0DJ, Velika Britanija ali
Sorbitol solution (3.2 g, 10.2 g, 13.4 g)/ Lamivudine 
Raztopina sorbitola (3,2 g , 10,2 g, 13,4 g)/lamivudin
HIV infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). 
Okužba s HIV se širi s spolnimi stiki z okuženo osebo ali z okuženo krvjo (npr. s skupno uporabo injekcijskih igel).
If your doctor advises that you can start taking Trizivir again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it. 
Če vam zdravnik svetuje, da začnite zdravilo Trizivir jemati znova, bo morda poskrbel, da prve odmerke vzamete v okolju, v katerem je na voljo zdravstvena oskrba, če bi jo potrebovali.
It is important to read the information on the other side of this leaflet under ‘Other possible side effects of Trizivir'. 
Pomembno je, da preberete informacije na drugi strani tega navodila pod naslovom "Drugi možni neželeni učinki zdravila Trizivir".
Routine risk minimisation activities 
Rutinske aktivnosti za zmanjšanje tveganja
Frequencies are defined as very common (> 1/10), common (> 1/100 to < 1/10), uncommon (> 1/1000 to < 1/100), rare (> 1/10,000 to < 1/1000), very rare (< 1/10,000). 
Pogostnost je definirana kot: zelo pogosti (> 1/10), pogosti (> 1/100 do < 1/10), občasni (> 1/1.000 do < 1/100),
Patients receiving Trizivir should be frequently examined and questioned for signs of lipoatrophy. 
Bolnike, ki prejemajo zdravilo Trizivir, je treba pogosto pregledovati in vprašati po znakih lipoatrofije.
You need to know about important signs and symptoms to look out for while you are taking Trizivir. 
Poznati morate pomembne znake in simptome, na katere morate biti pozorni med jemanjem zdravila Trizivir.
Trizivir and similar medicines may cause side effects in unborn babies. 
Zdravilo Trizivir in podobna zdravila imajo lahko neželene učinke pri nerojenih otrocih.
However, their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. 
Glavni način njihovega protivirusnega delovanja je vključitev monofosfatne oblike v verigo virusne DNK, kar ima za posledico prekinitev verige.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, 
Glaxo Operations UK Ltd, (trži Glaxo Wellcome Operations), Priory Street,
The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues. 
Izbira te fiksne kombinacije ne sme temeljiti le na rutini, ampak predvsem na pričakovani učinkovitosti in tveganjih,
The usual dose of Trizivir for adults is one tablet twice a day. 
Običajni odmerek pri odraslih je ena tableta dvakrat dnevno.
In this study, addition of ABC to ZDV/3TC/EFV did not significantly improve efficacy. 
V tej študiji dodatek ABC k shemi ZDV/3TC/EFV ni pomembneje izboljšal učinkovitosti.
Talk to your doctor before you start taking it again. 
Posvetujte se z zdravnikom, preden ga začnete jemati znova.
The recommended dose of Trizivir in adults (18 years and over) is one tablet twice daily. 
Priporočeni odmerek zdravila Trizivir za odrasle (stare 18 let in več) je ena tableta dvakrat dnevno.
Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction. 
Abakavir lahko povzroči resno alergijsko reakcijo znano kot preobčutljivostna reakcija.
The safety and efficacy of Trizivir in adolescents and children has not been established. 
Varnost in učinkovitost zdravila Trizivir pri mladostnikih in otrocih nista bili dokazani.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
Preobčutljivost na zdravilne učinkovine ali katerokoli pomožno snov, navedeno v poglavju 6.1.
If you are pregnant, if you become pregnant or if you are planning to become pregnant, talk to your doctor about the risks and benefits to you and your baby of taking Trizivir during your pregnancy. 
Nosečnost Če ste noseči, če zanosite ali če nameravate zanositi, se takoj posvetujte z zdravnikom o tveganjih in koristih jemanja zdravila Trizivir med nosečnostjo.
It is recommended that treatment is started with abacavir, lamivudine, and zidovudine separately for the first 6-8 weeks (see section 4.4). 
Priporočljivo je, da se zdravljenje prične z abakavirjem, lamivudinom in zidovudinom kot samostojnimi zdravili, kar naj traja prvih 6 do 8 tednov (glejte poglavje 4.4).
See your doctor as soon as possible. 
Čim prej obiščite zdravnika.
Antivirals for systemic use, antivirals for treatment of HIV infections, combinations. 
Antivirusna zdravila za sistemsko uporabo, antivirusna zdravila za zdravljenje HIV, kombinacije.
Your doctor may advise you to stop taking Trizivir. 
Zdravnik vam bo morda svetoval, da nehate jemati zdravilo Trizivir.
Rare: anxiety, depression 
Redki: anksioznost, depresija
The EU SPC provides detailed information and advice relating to ABC HSR 
EU SPC vsebuje podrobne informacije in nasvete v zvezi s preobčutljivostnimi reakcijami na ABC
Symptoms usually include fever, plus some of the following: 
Simptomi po navadi vključujejo povišano telesno temperaturo in še nekaj od naslednjega:
What Trizivir is and what it is used for What you need to know before you take Trizivir How to take Trizivir 
Kaj je zdravilo Trizivir in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Trizivir Kako jemati zdravilo Trizivir
These changes are not considered clinically relevant and no food restrictions are recommended for administration of Trizivir. 
Te spremembe se ne smatrajo kot klinično pomembne, zato pri dajanju zdravila Trizivir ni priporočil o omejitvah pri uživanju hrane.
Virologic failure (HIV RNA >200 copies/ml) 
Virološki neuspeh (HIV RNA > 200 kopij/ml)
In addition, the 69 insertion complex or the Q151M mutation, usually found in combination with A62V, V75I, F77L and F116Y, cause a high level of resistance to abacavir. 
Poleg tega je sta insercijski kompleks na mestu 69 ali mutacija Q151M, običajno ugotovljena v kombinaciji z A62V, V75I, F77L in F116Y, povzročila visoko stopnjo odpornosti proti abakavirju.
Virologic success (48 weeks HIV RNA < 50 copies/ml) 
Virološki uspeh (48 tednov HIV RNA < 50 kopij/ml)
Therefore, there is little potential for interactions with antiretroviral protease inhibitors, nonnucleosides and other medicinal products metabolised by major P450 enzymes. 
Torej obstaja le majhna možnost za interakcije s protiretrovirusnimi zaviralci proteaz, z nenukleozidi in drugimi zdravili, ki se presnavljajo z glavnimi encimi iz skupine P450.
If you are hypersensitive to Trizivir, return all your unused Trizivir tablets for safe disposal. 
Če ste preobčutljivi na zdravilo Trizivir, vse neporabljene tablete zdravila Trizivir vrnite, da jih bodo varno uničili.
There are no data on the use of Trizivir in pregnancy. 
Podatkov o uporabi zdravila Trizivir med nosečnostjo ni.
Currently there are no data on the use of Trizivir in heavily pre-treated patients, patients failing on other therapies or patients with advanced disease (CD4 cells < 50 cells/mm3). 
Trenutno ni podatkov o uporabnosti zdravila Trizivir pri bolnikih, ki so bili predhodno intenzivno zdravljeni, pri bolnikih pri katerih so bila druga zdravljenja neuspešna, ali pri bolnikih z napredovalo boleznijo (CD4 celice < 50 celic/mm3).
A modest increase in Cmax (28 %) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered. 
Opazili so zmeren porast Cmax (28 %) zidovudina, če so ga dajali skupaj z lamivudinom, vendar se celotna izpostavljenost (AUC) ni signifikantno spremenila.
• chest pain; disease of the heart muscle (cardiomyopathy) 
• bolečine v prsih; bolezen srčne mišice (kardiomiopatija),
Signs of osteonecrosis include: 
Med znaki osteonekroze so:
When prescribing Trizivir, action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). 
Ko predpisujete zdravilo Trizivir, poizkusite zmanjšati vse prilagodljive dejavnike tveganja (npr. kajenje, hipertenzijo in hiperlipidemijo).
• Additional risk minimisation measures 
• Dodatni ukrepi za zmanjšanje tveganj
Zidovudine has no effect on the pharmacokinetics of lamivudine. 
Zidovudin ne vpliva na farmakokinetične lastnosti lamivudina.
With this condition, parts of the bone tissue die because of reduced blood supply to the bone. 
Pri tej motnji deli kostnega tkiva odmrejo zaradi zmanjšane oskrbe kosti s krvjo.
Appropriate use of abacavir can be guided using currently recommended resistance algorithms. 
Za ustrezno uporabo abakavirja je potrebno upoštevati trenutno veljavne algoritme odpornosti.
You may need extra check-ups, including blood tests, while you are taking your medicine. 
Morda boste med jemanjem tega zdravila potrebovali dodatne kontrole, vključno s preiskavami krvi.
• In order to avoid restarting abacavir patients who have experienced a suspected HSR should be instructed to dispose of their remaining Trizivir tablets 
• Da bi preprečili ponovno uporabo abakavirja, je treba bolnikom, ki so imeli sum na HSR, naročiti, naj preostale tablete zdravila Trizivir zavržejo.
INFORMATION IN BRAILLE trizivir 
PODATKI V BRAILLOVI PISAVI trizivir
Patients with end-stage renal disease. 
Bolniki s terminalnim stadijem ledvične bolezni.
• difficulty moving 
• težave pri gibanju.
Swallow the tablets whole, with some water. 
Tablete pogoltnite cele z vodo.
• enlarged breasts in men 
• povečanje prsi pri moških.
• other medicinal products containing lamivudine, used to treat HIV infection or hepatitis B 
• drugih zdravil, ki vsebujejo lamivudin, ki se uporablja za zdravljenje okužbe s HIV ali okužbe s hepatitisom B,